FOLH1 and posterior cortical atrophy: In our previous prospective clinical trial on a cohort of 9 treatment-naïve PCa patients, we demonstrated a heterogeneous increase in PSMA uptake after 3–4 weeks of ADT, most evidently seen in bone lesions, followed mainly by a decrease of the uptake at 6–8 weeks after the initiation of the treatment [13].